Abbott Sees Absorb Bioresorbable Implant As Stent Market Game Changer
This article was originally published in The Pink Sheet Daily
The firm announced CE mark clearance Jan. 10, making Absorb the first drug-eluting bioresorbable vascular scaffold available to treat coronary artery disease. Abbott expects to submit a PMA by 2015.
You may also be interested in...
HeartWare HVAD submission
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.